ZA200504016B - Genetic constructs and compositions comprising RRE and CTE and uses thereof - Google Patents
Genetic constructs and compositions comprising RRE and CTE and uses thereof Download PDFInfo
- Publication number
- ZA200504016B ZA200504016B ZA200504016A ZA200504016A ZA200504016B ZA 200504016 B ZA200504016 B ZA 200504016B ZA 200504016 A ZA200504016 A ZA 200504016A ZA 200504016 A ZA200504016 A ZA 200504016A ZA 200504016 B ZA200504016 B ZA 200504016B
- Authority
- ZA
- South Africa
- Prior art keywords
- coding sequence
- hiv
- protein
- nucleic acid
- composition
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 108091026890 Coding region Proteins 0.000 claims abstract description 146
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 100
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 92
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 64
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 63
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 63
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 61
- 101710172711 Structural protein Proteins 0.000 claims abstract description 49
- 230000002163 immunogen Effects 0.000 claims abstract description 46
- 238000000034 method Methods 0.000 claims abstract description 46
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 claims abstract description 34
- 230000028993 immune response Effects 0.000 claims abstract description 14
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 239000013612 plasmid Substances 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020004414 DNA Proteins 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims 9
- 102000053602 DNA Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 10
- 230000032258 transport Effects 0.000 description 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101710150344 Protein Rev Proteins 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- -1 CD86 Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001559589 Cullen Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000714229 Simian retrovirus 1 Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42785602P | 2002-11-19 | 2002-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504016B true ZA200504016B (en) | 2006-08-30 |
Family
ID=32326604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504016A ZA200504016B (en) | 2002-11-19 | 2005-05-18 | Genetic constructs and compositions comprising RRE and CTE and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7455841B2 (ko) |
| EP (1) | EP1570051B1 (ko) |
| JP (1) | JP2006506094A (ko) |
| KR (1) | KR101159519B1 (ko) |
| CN (1) | CN100379853C (ko) |
| AT (1) | ATE447008T1 (ko) |
| AU (1) | AU2003291086B2 (ko) |
| BR (1) | BR0316722A (ko) |
| CA (1) | CA2506695A1 (ko) |
| CO (1) | CO5650177A2 (ko) |
| DE (1) | DE60329862D1 (ko) |
| IL (1) | IL168614A (ko) |
| MX (1) | MXPA05005329A (ko) |
| NZ (1) | NZ540152A (ko) |
| WO (1) | WO2004045548A2 (ko) |
| ZA (1) | ZA200504016B (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
| CN101472914B (zh) | 2006-04-20 | 2015-05-20 | 詹森药业有限公司 | C-fms激酶抑制剂 |
| JP2010512782A (ja) * | 2006-12-20 | 2010-04-30 | ジ チャン ユウ， | Ｈｉｖのｎｃ蛋白質発現用ベクター及びこれを利用したｎｃ蛋白質の生産方法 |
| EP2996697B1 (en) | 2013-05-15 | 2019-06-26 | Robert Kruse | Intracellular translation of circular rna |
| US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US554528A (en) * | 1896-02-11 | John m | ||
| US5604114A (en) * | 1986-05-20 | 1997-02-18 | Dana-Farber Cancer Institute | Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use |
| US5554528A (en) * | 1987-08-21 | 1996-09-10 | Board Of Revents Of University Of Colorado | Compositions and methods for inhibition of HIV production |
| US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| JP4041535B2 (ja) * | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5981505A (en) * | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5739118A (en) * | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5585263A (en) * | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
| US5650309A (en) * | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US6057095A (en) * | 1997-07-11 | 2000-05-02 | Medical University Of South Carolina | Screening procedure for inhibitors of HIV Rev function |
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
-
2003
- 2003-11-19 WO PCT/US2003/036924 patent/WO2004045548A2/en active Application Filing
- 2003-11-19 NZ NZ540152A patent/NZ540152A/en not_active IP Right Cessation
- 2003-11-19 EP EP03783674A patent/EP1570051B1/en not_active Expired - Lifetime
- 2003-11-19 JP JP2004553917A patent/JP2006506094A/ja active Pending
- 2003-11-19 AT AT03783674T patent/ATE447008T1/de not_active IP Right Cessation
- 2003-11-19 MX MXPA05005329A patent/MXPA05005329A/es active IP Right Grant
- 2003-11-19 CN CNB2003801089135A patent/CN100379853C/zh not_active Expired - Fee Related
- 2003-11-19 CA CA002506695A patent/CA2506695A1/en not_active Abandoned
- 2003-11-19 US US10/535,326 patent/US7455841B2/en not_active Expired - Lifetime
- 2003-11-19 KR KR1020057009084A patent/KR101159519B1/ko not_active IP Right Cessation
- 2003-11-19 DE DE60329862T patent/DE60329862D1/de not_active Expired - Lifetime
- 2003-11-19 BR BR0316722-4A patent/BR0316722A/pt not_active IP Right Cessation
- 2003-11-19 AU AU2003291086A patent/AU2003291086B2/en not_active Ceased
-
2005
- 2005-05-16 IL IL168614A patent/IL168614A/en not_active IP Right Cessation
- 2005-05-18 ZA ZA200504016A patent/ZA200504016B/en unknown
- 2005-05-19 CO CO05048670A patent/CO5650177A2/es not_active Application Discontinuation
-
2008
- 2008-11-20 US US12/275,192 patent/US8685407B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006506094A (ja) | 2006-02-23 |
| US7455841B2 (en) | 2008-11-25 |
| NZ540152A (en) | 2008-03-28 |
| US20060140978A1 (en) | 2006-06-29 |
| WO2004045548A2 (en) | 2004-06-03 |
| EP1570051A2 (en) | 2005-09-07 |
| AU2003291086A1 (en) | 2004-06-15 |
| KR20050083919A (ko) | 2005-08-26 |
| BR0316722A (pt) | 2005-10-18 |
| US20090170800A1 (en) | 2009-07-02 |
| CN100379853C (zh) | 2008-04-09 |
| WO2004045548A3 (en) | 2004-09-10 |
| ATE447008T1 (de) | 2009-11-15 |
| DE60329862D1 (de) | 2009-12-10 |
| AU2003291086B2 (en) | 2009-02-05 |
| KR101159519B1 (ko) | 2012-06-25 |
| EP1570051A4 (en) | 2006-02-15 |
| IL168614A (en) | 2011-03-31 |
| US8685407B2 (en) | 2014-04-01 |
| CA2506695A1 (en) | 2004-06-03 |
| CO5650177A2 (es) | 2006-06-30 |
| CN1738897A (zh) | 2006-02-22 |
| EP1570051B1 (en) | 2009-10-28 |
| MXPA05005329A (es) | 2005-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4580410B2 (ja) | 改善された免疫応答を誘導し得る発現ベクターおよびこのベクターの使用方法 | |
| JP4805511B2 (ja) | Ｈｉｖに対する免疫応答における改善、または免疫応答に関する改善 | |
| CN1764474B (zh) | 免疫原性组合物及方法 | |
| Otten et al. | Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins | |
| CN102782136A (zh) | 表达hiv抗原和gm-csf的载体和用于产生免疫应答的相关方法 | |
| US20110045017A1 (en) | Hiv vaccine for mucosal delivery | |
| KR20000070865A (ko) | 합성 ＨＩＶ ｇａｇ 유전자 | |
| JP2010265313A (ja) | ３つの完全な転写単位を有するプラスミドおよびｈｉｖに対する免疫応答を誘発するための免疫原組成物 | |
| US8685407B2 (en) | Genetic constructs and compositions comprising RRE and CTE and uses thereof | |
| Sykes et al. | Genetic live vaccines mimic the antigenicity but not pathogenicity of live viruses | |
| WO2021081437A2 (en) | Compositions comprising v2 opt hiv envelopes | |
| JP2024509123A (ja) | 合成リボ核酸（ｒｎａ）からのタンパク質発現を向上させる組換え発現構築物 | |
| Muthumani et al. | Issues for improving multiplasmid DNA vaccines for HIV-1 | |
| NZ525283A (en) | Conditionally replicating vectors, methods for their production and use | |
| US20130302368A1 (en) | Advanced Prime and Boost Vaccine | |
| US20080234215A1 (en) | DNA composition and uses thereof | |
| CN102085377B (zh) | 免疫原性组合物及方法 | |
| Smith | Design and immunogenicity of a DNA vaccine against primate lentiviruses | |
| KR20040039387A (ko) | Ｈｉｖ-ｇａｇ 코돈-최적화된 ｄｎａ 백신 | |
| CN101420976A (zh) | 用于产生免疫应答的组合方法 |